The emerging roles of CDK12 in tumorigenesis

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• Cyclin-dependent kinases (CDKs) are crucial regulators of cell cycle and transcription.
• CDK dysregulation is a common driver of tumorigenesis, making CDKs attractive cancer therapy targets.
• Cyclin-dependent kinase 12 (CDK12) is a transcription-associated kinase involved in DNA damage response, development, differentiation, splicing, and pre-mRNA processing.

Purpose of the Study:

• To review the current understanding of CDK12's role in ovarian and breast cancer.
• To explore the potential of CDK12 chemical inhibitors for future cancer treatments.

Main Methods:

• Literature review of existing research on CDK12.
• Analysis of CDK12's function in cell cycle regulation and transcription.
• Examination of CDK12's involvement in DNA damage response and RNA processing.

Main Results:

• CDK12 mutations (loss-of-function) are observed in high-grade serous ovarian carcinomas, suggesting a tumor suppressor role.
• CDK12 overexpression in other cancers indicates potential oncogenic properties, similar to other transcription-associated kinases.
• The dual role of CDK12 in tumorigenesis necessitates careful consideration for therapeutic targeting.

Conclusions:

• CDK12 exhibits context-dependent roles in tumorigenesis, acting as both a potential tumor suppressor and oncogene.
• Targeting CDK12 with chemical inhibitors presents a promising avenue for novel cancer therapies, particularly for ovarian and breast cancers.
• Further research is needed to fully elucidate CDK12's complex functions and optimize therapeutic strategies.